Author

@fwpharma fwpharma

grade Bcorporatex.com/fwpharma ↗

Biopharma trade-press feed relaying FDA, clinical, M&A and earnings news in real time

FirstWord Pharma's account broadcasts comprehensive, first-p

trader score
+0.98
hit rate
65%
mean α
+0.41%
signals 14d
65

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.

Their picks, scored

Across their last 20 scored bets: 65% hit rate, +0.41% mean alpha, trader score +0.98. Their last-14d mentions, direction-adjusted, have moved -1.6% since posting (mean over 31 mentions with price data).

Recent signals15receipts included
date (PT)tickerauthorsentwhat they saidsince thenreceipt
2026-08-28BNTX@fwpharma-0.45BioNTech ends a colorectal study of its mRNA vaccine.
2026-08-28TEVA@fwpharma-0.10Teva bids up to 125M for BioXcel neuroscience assets in a bankruptcy sale.
2026-08-28BTAI@fwpharma+0.50Teva bids up to 125M for BioXcel neuroscience assets in a bankruptcy sale.·
2026-08-28IONS@fwpharma-0.15Reports an AstraZeneca ATTR-CM study miss that raises questions for competing therapies.·
2026-08-28ALNY@fwpharma-0.15Reports an AstraZeneca ATTR-CM study miss that raises questions for competing therapies.
2026-08-28AZN@fwpharma-0.45Reports an AstraZeneca ATTR-CM study miss that raises questions for competing therapies.
2026-08-28RHHBY@fwpharma+0.25Roche signs an antibody-drug-conjugate deal with DualityBio worth more than 1B.
2026-08-28CYTK@fwpharma+0.30Reports Cytokinetics is preparing an FDA filing for non-obstructive HCM.
2026-08-27BMY@fwpharma+0.20Reports BMS committed another $173M to radiopharmaceutical manufacturing.-0.6%
2026-08-27GILD@fwpharma+0.50Reports FDA approval of Gilead's daily HIV treatment pill Bixlenvo.-2.1%
2026-08-27ROIV@fwpharma+0.50Priovant's inhibitor received FDA approval for dermatomyositis.·
2026-08-27·@fwpharma·Gates committed $35 million to ProFound's preeclampsia proteomics work.·
2026-08-27MRNA@fwpharma-0.30Moderna is moving to raise $2 billion after a cancer-vaccine win.-3.3%
2026-08-27AMGN@fwpharma+0.40A pivotal Tezspire study win supports pursuit of a third indication in eosinophilic oesophagitis.-1.0%
2026-08-27AZN@fwpharma+0.40A pivotal Tezspire study win supports pursuit of a third indication in eosinophilic oesophagitis.-1.1%

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.